The Shotlee Journal
Browse Shotlee articles about Metabolic Health.
Showing 9 / 744 Metabolic Health articles
Consumers are shifting from short-term fixes to proactive long-term gut health strategies, accelerated by GLP-1 medications, according to Kerry representatives Mathieu Millette, Ph.D., and Haelim Choi. Kerry research highlights top-valued benefits, while GLP-1 demand drives GI support innovations, including biotics tested in human trials to counter side effects.
Hims & Hers Health (NYSE: HIMS) is now offering a waitlist for affordable branded Wegovy and Ozempic at $149, thanks to a new Novo Nordisk deal. This expands access to these popular GLP-1 weight-loss drugs amid high demand. Meanwhile, HIMS stock shows short-term rebound potential in a downtrend—dive into the technicals and analyst views.
Researchers at Mass General Brigham have launched a revolutionary genetic risk calculator that not only forecasts obesity and Type 2 diabetes but also their long-term health consequences. Powered by data from over 8.5 million participants worldwide, this polygenic risk score outperforms existing tools, especially in diverse populations. Discover why this could enable earlier interventions like GLP-1 medications.
When celebrities drop dress sizes fast, whispers of 'fat jabs' like Ozempic fill the air—but stars stay mum. A veteran celeb agent exposes the regulatory pitfalls, contract traps, and multimillion-dollar reasons behind the secrecy. From TV bans to brand conflicts, here's why honesty could cost them dearly.
Side-by-side photos from 2019 and 2025 make Rebel Wilson's facial transformation after shedding over 80 pounds strikingly apparent. Noticeable changes include reduced volume, minor skin elasticity loss in cheeks, neck, and around lips and eyes, plus a sharper jawline. While many attribute it to Ozempic, Wilson clarifies its limited role in her journey.
Semaglutide prices in India are poised for a dramatic drop to one-fourth of current levels following patent expiry on March 20. Generics from seven companies like Sun Pharma and Zydus Lifesciences will make Ozempic and Wegovy alternatives more accessible for diabetes and obesity management. Experts highlight improved adherence but warn of misuse risks.
Sydney's superstar chef Neil Perry, behind Gran Torino, Margaret, and Qantas menus, isn't fazed by the Ozempic craze. He pledges to continue creating beautiful food for those who love to eat. In a bold GLP-1 warning, Perry hints at potential lawsuits ahead.
Biomea Fusion has released promising Phase II data from the COVALENT-111 study, demonstrating icovamenib's ability to significantly reduce HbA1c levels in specific diabetes patient subgroups over 52 weeks. With no serious treatment-related adverse events and durable effects nine months post-dosing, this oral menin inhibitor could offer new options for metabolic disease management. Investors note positive stock momentum amid upcoming trials.
Social media buzz highlights itchy skin as a surprising side effect of GLP-1 medications like semaglutide (Ozempic, Wegovy). Patients report hives and mosquito-like bites after doses. Dermatologists and weight loss experts break down causes from allergies to rapid weight loss and offer practical advice.
